• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

    2.125 +0.285 (+15.49%)
    Streaming Delayed Price Updated: 3:26 PM EDT, May 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fate Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗
     
    Via Benzinga
    News headline image
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Present at Upcoming March Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗
     
    Via Benzinga
    News headline image
    Recap: Fate Therapeutics Q4 Earnings ↗
     
    Via Benzinga
    News headline image
    A Preview Of Fate Therapeutics's Earnings ↗
     
    Via Benzinga
    News headline image
    Analyst Ratings for Fate Therapeutics ↗
     
    Via Benzinga
    News headline image
    Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    News headline image
    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Recap: Fate Therapeutics Q3 Earnings ↗
     
    Via Benzinga
    Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
    Via Investor Brand Network
    News headline image
    Analyst Ratings for Fate Therapeutics ↗
     
    Via Benzinga
    News headline image
    The Latest Analyst Ratings for Fate Therapeutics ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For February 26, 2024 ↗
    Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
    Via Benzinga
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗
    Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
    Via InvestorPlace
    News headline image
    Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
    U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
    Via Benzinga
    Topics Stocks
    News headline image
    Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics to Present at Upcoming September Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stocks That Hit 52-Week Lows On Tuesday ↗
      On Tuesday, 46 stocks hit new 52-week lows. 
    Via Benzinga
    News headline image
    Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.